Skip to main content
Caplight Logo









ATXA Therapeutics

ATXA Therapeutics

Private
DublinHealthcare & Life Scienceshttps://www.atxatherapeutics.com/

Last Round

Crowdfunding

Jan 22, 2024

Est. Valuation

$37.46M

Total Funding Raised

$10.14M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ATXA Therapeutics is a clinical-stage pharmaceutical company that develops novel, life-changing treatments for cardiopulmonary diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

pulmonary arterial hypertensionPAHsmall molecule drugthromboxane receptor antagonistTP antagonistclinical-stage pharmaorphan drug designationorphan drugcardiopulmonary diseasedrug discoveryPAH therapyphase I trialpharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ATXA Therapeutics Comparables

Compare ATXA Therapeutics with similar companies based on industry and business-model similarity.

ATXA Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cereno Scientific
78%
Sumitomo Pharma Co., Ltd.
71%
Gossamer Bio
71%

ATXA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingJan 22, 2024
GrantOct 21, 2022
GrantOct 31, 2018
SeedApr 1, 2018

Key People

Founding team and executive leadership

Therese Kinsella

Chief Executive Officer

Executive Team

ATXA Therapeutics Investors

Notable investors and investment history

ATXA Therapeutics investors
InvestorRounds
European Innovation Council FundGrant
European CommissionGrant
Spark Venture FundingCrowdfunding
Enterprise IrelandSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 35% MoM.

  • Jan 5, 2026

    Monthly visitors increased 51% MoM.

ATXA Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ATXA Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ATXA Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin
Employee Range5
Year Founded2015
Last FundingJan 22, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?